SecProbe.io

November 27, 2019
B. Sonny Bal, M.D.
President and Chief Executive Officer
Sintx Technologies, Inc.
1885 West 2100 South
Salt Lake City, UT 84119
Re:Sintx Technologies, Inc.
Registration Statement on Form S-1
Filed November 1, 2019
File No. 333-234438
Dear Dr. Bal:
            We have limited our review of your registration statement to those issues we have
addressed in our comments.  In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1 filed November 1, 2019
Cover page
1.We note your disclosure that you may extend the rights offering in your sole discretion.
Please revise your disclosure to state a termination date that is not indefinite. Refer to Item
501(b)(8)(iii) of Regulation S-K.
The Rights Offering
No Revocation or Change, page 25
2.We note your disclosure that all exercises of subscription rights are irrevocable even if
purchasers learn information about you that purchasers consider to be unfavorable. Please
tell us the circumstances under which you will provide your shareholders with the right to
revoke subscriptions in the event of material developments during the offering period.

 FirstName LastNameB. Sonny Bal, M.D.
 Comapany NameSintx Technologies, Inc.
 November 27, 2019 Page 2
 FirstName LastName
B. Sonny Bal, M.D.
Sintx Technologies, Inc.
November 27, 2019
Page 2

            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
            Please contact Joe McCann at 202-551-6262 or Christine Westbrook at 202-551-5019
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       David F. Marx, Esq.